Tradewinds Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Tradewinds Capital Management’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13	Closed	-$118	–	720
2025 Q4	$118	Buy	+13	New	+$309	﹤0.01%	651

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Tradewinds Capital Management's APVO Position: Q1 2026 in Review

Tradewinds Capital Management sold out of Aptevo Therapeutics (APVO) in Q1 2026, closing a stake of 13 shares — an estimated $118 sold.

Tradewinds Capital Management first reported a position in APVO in Q4 2025 and held it in 1 quarter. The position peaked at $118 in Q4 2025. 9 funds tracked by Wall St. Rank hold APVO as of Q1 2026.

Tradewinds Capital Management reported no remaining Aptevo Therapeutics position as of Q1 2026 after selling out during the quarter.
Tradewinds Capital Management sold 13 Aptevo Therapeutics shares in Q1 2026, an estimated $118.
Tradewinds Capital Management first reported a position in Aptevo Therapeutics in Q4 2025 and held it in 1 quarter.
Tradewinds Capital Management's Aptevo Therapeutics position peaked at $118 in Q4 2025.
9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q1 2026.

Based on Tradewinds Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.